← All trials
NCT05905432
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 25, 2023
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jun 15, 2023
- Last posted
- Jul 24, 2023
- Enrollment
- 33
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Centre de Recherche Médicale de LambarénéLead sponsor
- Centre de Recherche Médicale de LambarénéReponsible party - principal investigator
- Global Health Innovative Technology FundCollaborator
- University of FloridaStudy director
- University of FloridaOfficial
- Centre de Recherche Médicale de LambarénéSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.